Boehringer Says Cephalon Ruling Can't Help Aggrenox Class
Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. have hit back at the class plaintiffs in the Aggrenox pay-for-delay litigation, saying the Pennsylvania federal judge's recent ruling denying summary judgment in...To view the full article, register now.
Already a subscriber? Click here to view full article